01776nam a2200277 4500 ESSALUD 20260903092258.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Maini, Luca Autor 54502 Medicaid’s GENEROUS Most-Favored-Nation Pricing Model — Promise and Limitations páginas: 1772-1774 On November 10, 2025, the Centers for Medicare and Medicaid Services (CMS) released a request for applications seeking pharmaceutical manufacturer participation in the GENEROUS (Generating Cost Reductions for U.S. Medicaid) model — a pilot program intended to reduce Medicaid drug spending and improve drug access. Under the program, participating manufacturers will offer supplemental rebates tied to prices in non-U.S. Group of Seven (G7) countries (Canada, France, Germany, Italy, Japan, and the United Kingdom) plus Denmark and Switzerland in exchange for federally negotiated coverage criteria. State Medicaid programs will then decide whether to accept those coverage terms. Participating states will forgo any additional state-specific rebates they previously negotiated but will retain Medicaid Drug Rebate Program (MDRP) statutory rebates. COSTO DE LA ATENCIÓN MÉDICA 54150 MEDICAMENTOS, DISPOSITIVOS Y LA FDA 54223 MEDICARE 54503 MEDICAID 54504 IMPLEMENTACIÓN DE LA REFORMA 54441 Sachs, Rachel E. 54505 Kyle, Michael Anne 54506 Kakani, Pragya 54507 22717 22676 Massachusetts NEJM Group NEJM015 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-31 sqb 22913 22913